Cyclooxygenase-2 (COX-2) (an
enzyme responsible for the conversion of
arachidonic acid to
prostaglandin) upregulation has been described in association with a variety of
tumors including
gliomas. This study reviews the immunohistochemical profile of 47
glioblastoma multiforme using COX-2 antibody and correlates the results with MIB-1 (marker of cell proliferation) immunostaining. Positive staining with COX-2 was observed in 35
tumors (74.5%); more than 10%
tumor cell positivity was seen in 10
tumors (21.3%). Immunostaining results were as follows: no staining, N = 12 (25.5%); 0% to 5% of
tumor cells, N = 20 (42.6%); 5% to 10%, N = 5 (10.6%); 10% to 20%, N = 4 (8.5%); 20% to 50%, N = 4 (8.5%); and greater than 50%, N = 2 (4.3%). The mean MIB-1 labeling index for all
tumors ranged from 3.0 to 76.4 (mean, 19.6). Mean MIB-1 labeling indices were higher in
tumors with greater than 5% COX-2 immunostaining (mean MIB-1 labeling index, 23.5) versus
tumors with 0% to 5% COX-2 immunostaining (mean MIB-1 labeling index, 17.7). There is evidence of COX-2 expression by immunohistochemistry in the majority of
glioblastoma multiforme. As a group,
tumors with a higher rate of cell proliferation tended to have increased expression of COX-2. These findings are significant in that therapeutic agents, which inhibit COX-2, are currently available and may play a role in the management of
glioblastoma multiforme.